This educational activity is supported by educational grants from the following companies: Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Relapsed or Refractory Multiple Myeloma

Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
The University of Arizona Cancer Center


Recent advances in the treatment of multiple myeloma have made prolonged remission possible for many patients. However, relapse remains inevitable for the majority of patients. This activity will provide the advanced practitioner with up-to-date information on monitoring for response and surveillance. In addition, the advanced practitioner will gain a deeper understanding of how clonal evolution and the mechanisms of action for various therapies impact clinical decision-making for older patients and patients with relapsed or refractory multiple myeloma.



Related Activities

Management of Newly Diagnosed Multiple Myeloma Patients

Management of Multiple Myeloma Patients Treated With Immunotherapy

Adjunctive and Supportive Care in Multiple Myeloma

Risk Stratification in Multiple Myeloma

How do IMIDs work?

What does an advanced practitioner need to know to create an optimal treatment regimen for the individual patient and explain the benefits and risks of the available choice to patients?

Briefly define low-risk vs high risk patient and how risk stratification influences treatment decisions.

What are the toxicities associated with the agents used for multiple myeloma?

What are some monitoring parameters for toxicities to establish?

How can I increase patient adherence to treatment regimens for multiple myeloma?

Bone Marrow Biopsy Demonstration Video



Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me